- Home
- TYRA vs ATEC Comparison
TYRA vs ATEC Comparison
Compare TYRA & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- ATEC
- Stock Information
- Founded
- TYRA 2018
- ATEC 1990
- Country
- TYRA United States
- ATEC United States
- Employees
- TYRA N/A
- ATEC N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- ATEC Medical/Dental Instruments
- Sector
- TYRA Health Care
- ATEC Health Care
- Exchange
- TYRA Nasdaq
- ATEC Nasdaq
- Market Cap
- TYRA 812.7M
- ATEC 1.3B
- IPO Year
- TYRA 2021
- ATEC 2006
- Fundamental
- Price
- TYRA $14.43
- ATEC $9.06
- Analyst Decision
- TYRA Strong Buy
- ATEC Strong Buy
- Analyst Count
- TYRA 5
- ATEC 11
- Target Price
- TYRA $31.00
- ATEC $17.82
- AVG Volume (30 Days)
- TYRA 201.5K
- ATEC 1.2M
- Earning Date
- TYRA 11-07-2024
- ATEC 02-25-2025
- Dividend Yield
- TYRA N/A
- ATEC N/A
- EPS Growth
- TYRA N/A
- ATEC N/A
- EPS
- TYRA N/A
- ATEC N/A
- Revenue
- TYRA N/A
- ATEC $572,739,000.00
- Revenue This Year
- TYRA N/A
- ATEC $27.98
- Revenue Next Year
- TYRA N/A
- ATEC $20.62
- P/E Ratio
- TYRA N/A
- ATEC N/A
- Revenue Growth
- TYRA N/A
- ATEC 27.21
- 52 Week Low
- TYRA $11.24
- ATEC $4.88
- 52 Week High
- TYRA $29.60
- ATEC $17.34
- Technical
- Relative Strength Index (RSI)
- TYRA 42.39
- ATEC 47.36
- Support Level
- TYRA $13.27
- ATEC $8.95
- Resistance Level
- TYRA $14.77
- ATEC $9.43
- Average True Range (ATR)
- TYRA 0.75
- ATEC 0.45
- MACD
- TYRA 0.07
- ATEC -0.10
- Stochastic Oscillator
- TYRA 50.19
- ATEC 31.58
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About ATEC Alphatec Holdings Inc.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.